More than thirty targeted protein degraders are now in human trials, with the first Phase 3 readouts arriving in 2026. Inside the vepdegestrant breast cancer data, the BTK degrader race,…
A major study being presented this week at the American Society of Clinical Oncology’s annual meeting found that patients with early-stage cancer who took GLP-1 receptor agonists were 38 to…
AI drug discovery is not one breakthrough. It is a stack of tools for target discovery, molecule design, toxicity prediction, clinical trials, and repurposing — each with a different burden…
The AI drug discovery market is projected to grow from $8.8 billion in 2026 to $114.4 billion by 2033. The bigger story is whether AI can turn better maps of…
As of May 2026, more than 75 AI-discovered drugs are in human trials. Inside the Insilico IPF Phase 2 program, Isomorphic Labs partnerships with Novartis and Lilly, Recursion’s Phase 2…
A new KRAS-targeting oral drug called daraxonrasib has nearly doubled survival in metastatic pancreatic cancer, with median overall survival of 13.2 months versus 6.7 months on chemotherapy in the landmark…
A decade of senolytic research is converging into something new. Inside the Mayo Clinic dasatinib quercetin work, the AFFIRM-LITE fisetin trial, Rubedo’s March 2026 Phase 1 readout of RLS-1496, and…
An estimated 1.4 billion people globally carry elevated lipoprotein(a), a genetically inherited cardiovascular risk factor that statins do not lower. Inside the biology of Lp(a), why the science went quiet…
Adrian Woolfson trained under a Nobel laureate at Cambridge, ran global oncology programs at the world’s largest pharmaceutical companies, and led research and development at Sangamo Therapeutics during the first…
For four decades, a single protein drove roughly a third of all human cancers, and nobody could build a drug against it. Here is why that story is finally changing,…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.